12:59 PM
 | 
Dec 14, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Darzalex combo meets PFS endpoint in first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) and Janssen Biotech Inc. said Darzalex daratumumab plus Revlimid lenalidomide and dexamethasone met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAIA trial to treat newly diagnosed multiple myeloma. Median PFS has not yet been reached in the Darzalex arm at a median follow-up of 28 months vs. 31.9 months...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >